Insider Selling: PACS Group (NYSE:PACS) CEO Sells $396,098.36 in Stock

PACS Group, Inc. (NYSE:PACS) CEO Jason Murray sold 8,771 shares of PACS Group stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $45.16, for a total value of $396,098.36. Following the completion of the transaction, the chief executive officer directly owned 54,566,095 shares in the company, valued at approximately $2,464,204,850.20. This represents a 0.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jason Hulse Murray also recently made the following trade(s):

• On Monday, September 14th, Jason Murray sold 317 shares of PACS Group stock. The shares were sold at an average price of $45.03, for a total value of $14,274.51.
• On Friday, September 11th, Jason Murray sold 10,529 shares of PACS Group stock. The stock was sold at an average price of $45.23, for a total transaction of $476,226.67.
• On Wednesday, September 9th, Jason Murray sold 4,758 shares of PACS Group stock. The shares were sold at an average price of $43.33, for a total transaction of $206,164.14.
• On Tuesday, September 8th, Jason Murray sold 24,057 shares of PACS Group stock. The stock was sold at an average price of $43.49, for a total transaction of $1,046,238.93.
• On Friday, September 4th, Jason Murray sold 23,072 shares of PACS Group stock. The stock was sold at an average price of $42.69, for a total transaction of $984,943.68.
• On Thursday, September 3rd, Jason Murray sold 20,173 shares of PACS Group stock. The shares were sold at an average price of $42.56, for a total transaction of $858,562.88.
• On Wednesday, September 2nd, Jason Murray sold 23,783 shares of PACS Group stock. The shares were sold at an average price of $42.94, for a total transaction of $1,021,242.02.
• On Tuesday, September 1st, Jason Murray sold 24,157 shares of PACS Group stock. The stock was sold at an average price of $42.39, for a total value of $1,024,015.23.
• On Friday, August 21st, Jason Murray sold 59,244 shares of PACS Group stock. The shares were sold at an average price of $43.90, for a total value of $2,600,811.60.
• On Thursday, August 20th, Jason Murray sold 91,306 shares of PACS Group stock. The shares were sold at an average price of $43.92, for a total value of $4,010,159.52.

PACS Group Trading Up 1.5%

PACS Group stock opened at $42.72 on Thursday. The business has a 50 day moving average price of $44.69 and a two-hundred day moving average price of $39.14. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.21. PACS Group, Inc. has a 12 month low of $10.31 and a 12 month high of $49.49. The stock has a market cap of $6.76 billion, a price-to-earnings ratio of 24.84, a price-to-earnings-growth ratio of 1.31 and a beta of -0.13.

PACS Group (NYSE:PACS) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.09. The company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.41 billion. PACS Group had a return on equity of 29.55% and a net margin of 4.85%. As a group, equities analysts forecast that PACS Group, Inc. will post 2.13 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on PACS shares. Truist Financial set a $62.00 price objective on shares of PACS Group in a research note on Wednesday, September 2nd. Royal Bank Of Canada raised their price target on shares of PACS Group from $52.00 to $57.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Zacks Research downgraded PACS Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 9th. JPMorgan Chase & Co. increased their target price on PACS Group from $47.00 to $58.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. Finally, Oppenheimer raised their target price on PACS Group from $48.00 to $57.00 and gave the stock an “outperform” rating in a research report on Monday, August 10th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.80.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PACS. Tidal Investments LLC bought a new position in shares of PACS Group in the 2nd quarter valued at about $252,000. Engineers Gate Manager LP bought a new stake in shares of PACS Group during the second quarter worth approximately $1,132,000. Integrated Wealth Concepts LLC bought a new position in PACS Group in the second quarter valued at approximately $75,000. Squarepoint Ops LLC boosted its stake in PACS Group by 94.7% in the second quarter. Squarepoint Ops LLC now owns 59,523 shares of the company’s stock valued at $2,538,000 after acquiring an additional 28,945 shares during the last quarter. Finally, Nykredit A S acquired a new stake in PACS Group during the 2nd quarter worth $95,000.

More PACS Group News

Here are the key news stories impacting PACS Group this week:

• Positive Sentiment: Management provided updates on PACS Group’s growth strategy, including the Eduro and Florida acquisitions. The company’s focus on expanding its post-acute-care footprint could support future revenue and earnings growth. PACS growth strategy, Eduro and Florida acquisitions
• Positive Sentiment: PACS is reportedly using higher patient volume and mergers and acquisitions to offset managed-care pressures. If successful, the strategy could improve scale and help defend margins in a challenging reimbursement environment. PACS managed-care and M&A strategy
• Positive Sentiment: The latest reported quarter exceeded expectations, with earnings per share of $0.63 versus the $0.54 consensus estimate and revenue of $1.43 billion versus $1.41 billion expected. Analysts’ average price target remains about $58.80, above recent trading levels, with an overall “Moderate Buy” rating.
• Neutral Sentiment: Director Mark Hancock sold 144,318 shares for approximately $6.4 million on September 14 and another 155,682 shares for about $6.6 million on September 15. Both transactions were made under a pre-arranged Rule 10b5-1 plan, and Hancock still owns more than 53.5 million shares, limiting the signal from the sales. Mark Hancock PACS insider sales
• Negative Sentiment: CEO Jason Murray has also continued selling shares, including 317 shares on September 14 and 10,529 shares on September 11, following several larger sales earlier in the month. The transactions were conducted under a 10b5-1 plan, but repeated executive selling may create modest near-term pressure or investor concern. Jason Murray PACS insider sales

PACS Group Company Profile

PACS Group, Inc is a U.S. healthcare services company that operates skilled nursing and post-acute care facilities. Its facilities provide short-term rehabilitation, long-term skilled nursing, nursing care, and related clinical services for patients recovering from illness, injury, surgery, or hospitalization.

The company’s broader care offerings may include assisted living, memory care, behavioral health, and other specialized post-acute services, depending on the facility and market.